Clinical Trial Update: M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma. [Phase 3]

View source ↗

Summary

A phase 3 trial evaluating M108 plus CAPOX versus placebo plus CAPOX as first-line treatment for CLDN18.2-positive, HER2-negative, PD-L1 CPS<5 locally advanced …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• CAPOX (capecitabine + oxaliplatin)
• M108 (M108)

Snippet

Sponsor: FutureGen Biopharmaceutical (Beijing) Co., Ltd | Conditions: Locally Advanced Unresectable or Metastatic Gastric Cancer, Locally Advanced Unresectable or Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma | Phase 3 | Status: RECRUITING